Clinical Study

An Exploratory Phase II Study To Determine The Tolerability, Safety, And Activity Of A Novel Vasopressin 1A Receptor Antagonist (Srx246) In Irritable Subjects With Huntington's Disease (Hd)

Posted Date: Mar 6, 2017

  • Investigator: Andrew Duker
  • Co-Investigator: Molly Winters
  • Specialties: Neurology, Movement Disorders
  • Type of Study: Drug

We are doing this research to find out whether a new investigational drug called SRX246, which might be useful to HD patients who sometimes feel irritable, angry, or even aggressive, is well tolerated and safe when it is given two times a day by mouth at doses as high as 160 mg. As part of this study, we will use a number of questionnaires because we want to find out how much we can learn about how you feel based on the answers you give. This will let us and others plan future studies of medicines that may help HD patients control their temper better.


We Are Asking You To Take Part In This Research Study Because You Have Huntington's Disease (Hd). Subjects Must Have Clinical Features Of Hd, Which Can Include Motor, Cognitive, Or Behavioral Symptoms. A Confirmatory History Of Hd; Or Cab Repeat Expansion 37 Or Greater. In Addition A Total Functional Capacity Score Of 5-13 And Evidence Of Irritability.


Huntingtons, Srx246, Neurology, Movement, Null

For More Information:

Molly Winters

  • Search Clinical Studies

  • Research in the News

    Enhanced Recovery Program for Colorectal Surgery Patients Reduces Costs

    A standardized protocol for managing patients for the duration of colorectaloperations not only improved clinical outcomes, but also it significantlyreduced hospital costs.